X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (4105) 4105
humans (3583) 3583
mice (2977) 2977
rank ligand - metabolism (2698) 2698
female (1997) 1997
male (1941) 1941
osteoclasts - metabolism (1787) 1787
osteoprotegerin (1667) 1667
rank ligand (1564) 1564
rankl (1501) 1501
osteoclasts - cytology (1432) 1432
osteoclasts - drug effects (1393) 1393
cells, cultured (1352) 1352
osteoporosis (1183) 1183
receptor activator (1176) 1176
differentiation (1148) 1148
receptor activator of nuclear factor-kappa b (1119) 1119
expression (1096) 1096
rank ligand - genetics (1090) 1090
endocrinology & metabolism (1080) 1080
cell differentiation - drug effects (981) 981
osteoclast (961) 961
osteoprotegerin - metabolism (924) 924
cell biology (906) 906
osteoclastogenesis (885) 885
biochemistry & molecular biology (823) 823
middle aged (821) 821
bone resorption (820) 820
osteoclasts (815) 815
cells (793) 793
mice, inbred c57bl (793) 793
osteoblasts - metabolism (791) 791
cell differentiation (753) 753
cell line (748) 748
musculoskeletal diseases (723) 723
signal transduction (719) 719
bone (706) 706
adult (689) 689
gene expression (673) 673
osteoclast differentiation (661) 661
rats (657) 657
rank ligand - pharmacology (653) 653
kappa-b ligand (652) 652
bone-resorption (627) 627
nf-kappa b - metabolism (617) 617
activation (601) 601
aged (589) 589
analysis (589) 589
nf-kappa-b (571) 571
trance protein (570) 570
bone resorption - metabolism (569) 569
osteoclasts - physiology (560) 560
membrane glycoproteins - metabolism (546) 546
bone and bones - metabolism (541) 541
osteoclasts - pathology (541) 541
carrier proteins - metabolism (525) 525
immunology (520) 520
in-vitro (518) 518
ligand (515) 515
osteogenesis - drug effects (509) 509
receptor activator of nuclear factor-kappa b - metabolism (507) 507
osteoprotegerin - genetics (494) 494
rna, messenger - metabolism (490) 490
osteoblasts (489) 489
rank (484) 484
dentistry (481) 481
osteoblasts - drug effects (480) 480
dentistry, oral surgery & medicine (479) 479
cytokines (462) 462
orthopedics (454) 454
reverse transcriptase polymerase chain reaction (454) 454
inflammation (445) 445
signal transduction - drug effects (445) 445
bones (444) 444
mice, knockout (439) 439
tartrate-resistant acid phosphatase (439) 439
medicine, research & experimental (419) 419
ligands (407) 407
nfatc transcription factors - metabolism (405) 405
postmenopausal women (405) 405
rheumatology (404) 404
proteins (395) 395
osteoprotegerin ligand (394) 394
gene-expression (393) 393
apoptosis (391) 391
osteoblasts - cytology (384) 384
research (383) 383
rheumatoid-arthritis (382) 382
opg (380) 380
rank ligand - blood (380) 380
bone resorption - pathology (374) 374
resorption (372) 372
bone loss (367) 367
bone marrow cells - cytology (366) 366
immunohistochemistry (365) 365
oncology (362) 362
denosumab (361) 361
bone density (359) 359
disease models, animal (359) 359
rank ligand - antagonists & inhibitors (356) 356
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6304) 6304
Japanese (116) 116
Chinese (105) 105
Polish (17) 17
German (15) 15
French (9) 9
Spanish (9) 9
Russian (7) 7
Hungarian (6) 6
Korean (3) 3
Dutch (2) 2
Italian (2) 2
Portuguese (2) 2
Czech (1) 1
Danish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 2016, Volume 22, Issue 8, pp. 933 - 939
Individuals who have mutations in the breast-cancer-susceptibility gene BRCA1 (hereafter referred to as BRCA1-mutation carriers) frequently undergo... 
BRCA2 MUTATION CARRIERS | MEDICINE, RESEARCH & EXPERIMENTAL | TUMOR-DEVELOPMENT | BIOCHEMISTRY & MOLECULAR BIOLOGY | PROLIFERATION | OVARIAN-CANCER | CELL BIOLOGY | RISK-REDUCING SURGERY | STEM-CELL | MICE | DIFFERENTIAL EXPRESSION ANALYSIS | GLAND | MAMMARY EPITHELIAL-CELLS | Immunohistochemistry | Neoplasm Transplantation | RANK Ligand - metabolism | Humans | Molecular Targeted Therapy | Prophylactic Mastectomy | Stem Cells - metabolism | Breast - metabolism | Breast Neoplasms - metabolism | Denosumab - therapeutic use | Flow Cytometry | Organoids - metabolism | Female | Receptor Activator of Nuclear Factor-kappa B - metabolism | Disease Models, Animal | Carcinogenesis - genetics | Bone Density Conservation Agents - therapeutic use | Reverse Transcriptase Polymerase Chain Reaction | Bone Density Conservation Agents - pharmacology | Breast Neoplasms - prevention & control | Carcinogenesis - drug effects | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Animals | Breast Neoplasms - genetics | RANK Ligand - antagonists & inhibitors | Breast - drug effects | DNA Repair | Organoids - drug effects | Pilocarpine - analogs & derivatives | Stem Cells - drug effects | Heterozygote | Cell Proliferation - drug effects | Mice | Mutation | Denosumab - pharmacology | Tumor Suppressor Proteins | Care and treatment | Cytokines | BRCA mutations | Development and progression | Breast cancer | Genetic aspects | Health aspects | Ligands | Genes
Journal Article
Journal of clinical periodontology, ISSN 0303-6979, 2012, Volume 39, Issue 3, pp. 239 - 248
Background and Objectives The receptor activator of NF‐κB ligand‐osteoprotegerin (RANKL‐OPG) bi‐molecular system... 
gingival crevicular fluid | receptor activator of NF‐κB ligand | diagnostics | receptor activator of NF‐κB ligand/osteoprotegerin ratio | osteoprotegerin | periodontal disease | receptor activator of NF-ÎB ligand/osteoprotegerin ratio | receptor activator of NF-ÎB ligand | receptor activator of NF-?B ligand | DIFFERENTIAL EXPRESSION | osteoprotegerin ratio | NECROSIS-FACTOR-ALPHA | TRANSCRIPTION FACTOR NFATC1 | MESSENGER-RNA | DENTISTRY, ORAL SURGERY & MEDICINE | OSTEOPROTEGERIN LIGAND | RECEPTOR ACTIVATOR | OSTEOCLAST DIFFERENTIATION | KAPPA-B LIGAND | ALVEOLAR BONE DESTRUCTION | Alveolar Bone Loss - metabolism | Biomarkers - metabolism | Lymphocytes - metabolism | Alveolar Bone Loss - therapy | RANK Ligand - metabolism | Humans | Periodontitis - therapy | Diabetes Mellitus - metabolism | Periodontitis - blood | Gingival Crevicular Fluid - chemistry | Biomarkers - blood | Saliva - chemistry | Periodontal Ligament - metabolism | Periodontitis - metabolism | Dental Plaque - microbiology | Smoking - metabolism | RANK Ligand - blood | Animals | Gingiva - chemistry | Osteoporosis - metabolism | Osteoprotegerin - blood | Osteoprotegerin - metabolism | Osteoblasts - metabolism | Alveolar Bone Loss - blood | Oral hygiene | Immune system | Diabetes mellitus | biomarkers | Blood | Osteoprotegerin | Bone resorption | Osteoclastogenesis | Periodontal diseases | NF- Kappa B protein | Molecular modelling | Periodontitis | Gingiva | TRANCE protein | Saliva | Smoking
Journal Article
The Journal of immunology (1950), ISSN 1550-6606, 2005, Volume 174, Issue 11, pp. 6686 - 6691
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 04/2006, Volume 26, Issue 4, pp. 857 - 863
...), RANK, and RANK ligand (RANKL) in coronary artery disease. METHODS AND RESULTS—We examined the expression of various members of the OPG/RANKL/RANK axis in patients... 
Arteriosclerosis | Inflammation | Plaque stability | HEART-FAILURE | ATHEROSCLEROSIS | COMMON VARIABLE IMMUNODEFICIENCY | SERUM OSTEOPROTEGERIN LEVELS | PATHOGENESIS | arteriosclerosis | TUMOR-NECROSIS-FACTOR | inflammation | plaque stability | BIOLOGY | RECEPTOR ACTIVATOR | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | KAPPA-B LIGAND | ARTERY-DISEASE | Receptor Activator of Nuclear Factor-kappa B | Apolipoproteins E - deficiency | Membrane Glycoproteins - metabolism | Muscle, Smooth, Vascular - metabolism | Humans | Middle Aged | Glycoproteins - metabolism | Male | Monocytes - metabolism | RANK Ligand | Osteoprotegerin | Angina, Unstable - immunology | T-Lymphocytes - metabolism | Receptors, Tumor Necrosis Factor - blood | Adult | Female | T-Lymphocytes - pathology | Receptors, Tumor Necrosis Factor - metabolism | Angina, Unstable - metabolism | Cell Line | Atherosclerosis - pathology | Atherosclerosis - immunology | Rupture, Spontaneous - metabolism | Glycoproteins - blood | Rupture, Spontaneous - immunology | Atherosclerosis - metabolism | Mice, Knockout | Muscle, Smooth, Vascular - pathology | Receptors, Cytoplasmic and Nuclear - blood | Angina, Unstable - pathology | Animals | Carrier Proteins - metabolism | Apolipoproteins E - genetics | Aged | Mice | Matrix Metalloproteinases - metabolism | Receptors, Cytoplasmic and Nuclear - metabolism
Journal Article
Nature (London), ISSN 1476-4687, 2018, Volume 561, Issue 7722, pp. 195 - 200
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2016, Volume 11, Issue 5, p. e0154680
The receptor-activator of nuclear kappaB ligand (RANKL) signaling pathway plays an important role in the regulation of bone growth and mediates the formation and activation of osteoclasts... 
GIANT-CELL TUMOR | DENOSUMAB | MULTIDISCIPLINARY SCIENCES | Osteosarcoma - drug therapy | RANK Ligand - metabolism | Humans | Male | Antineoplastic Agents - therapeutic use | Fibrous Dysplasia of Bone - drug therapy | RNA, Messenger - metabolism | Bone Neoplasms - pathology | Giant Cell Tumor of Bone - pathology | Chondrosarcoma - genetics | Chondrosarcoma - pathology | Bone Cysts, Aneurysmal - metabolism | Bone Neoplasms - genetics | Fibrous Dysplasia of Bone - genetics | Chondroma - drug therapy | Osteoclasts - pathology | Bone Cysts, Aneurysmal - pathology | Multiple Myeloma - genetics | Osteosarcoma - pathology | Bone Cysts, Aneurysmal - drug therapy | Chondroma - genetics | Gene Expression Regulation, Neoplastic | Chondroma - metabolism | Chondroma - pathology | Bone Neoplasms - metabolism | Denosumab - therapeutic use | Multiple Myeloma - drug therapy | Giant Cell Tumor of Bone - drug therapy | RNA, Messenger - antagonists & inhibitors | Female | Bone Neoplasms - drug therapy | Giant Cell Tumor of Bone - genetics | Osteosarcoma - metabolism | Fibrous Dysplasia of Bone - pathology | RNA, Messenger - genetics | Multiple Myeloma - metabolism | Organ Specificity | Chondrosarcoma - drug therapy | Fibrous Dysplasia of Bone - metabolism | Osteoclasts - metabolism | Bone Resorption - prevention & control | RANK Ligand - genetics | Multiple Myeloma - pathology | Giant Cell Tumor of Bone - metabolism | RANK Ligand - antagonists & inhibitors | Chondrosarcoma - metabolism | Osteosarcoma - genetics | Osteoclasts - drug effects | Bone Cysts, Aneurysmal - genetics | Bone resorption | Bones | Dosage and administration | Denosumab | Growth | Analysis | Immunohistochemistry | Chondrosarcoma | Multiple myeloma | Aneurysm | Bone tumors | Metastasis | Bone surgery | Metastases | Osteoprotegerin | Ewings sarcoma | Signal transduction | Bone growth | Biomedical materials | Osteosarcoma | Fibrous dysplasia | Bone dysplasia | Biocompatibility | Lesions | TRANCE protein | University graduates | Statistical analysis | Bone lesions | Gene expression | Osteoclastogenesis | Signaling | Bone cancer | Hospitals | Biopsy | Stromal cells | Orthopedics | Monoclonal antibodies | Ligands | Osteoclasts | Prostate cancer | Tumors
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 11/2015, Volume 135, Issue 11, pp. 2884 - 2887